Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.26 USD | +2.44% | -1.56% | +7.69% |
05-13 | HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating | MT |
05-09 | Transcript : Clearside Biomedical, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.69% | 91.92M | |
+4.01% | 111B | |
+11.45% | 105B | |
-12.60% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.43% | 16.96B | |
+3.07% | 13.7B | |
+37.03% | 12.45B |
- Stock Market
- Equities
- CLSD Stock
- News Clearside Biomedical, Inc.
- Clearside Biomedical : Wedbush Adjusts PT on Clearside Biomedical to $18 From $6 on CLS-AX Potential in Treating Wet Age-Related Macular Degeneration; Outperform Rating Kept